Evaluating the Impact of Medicare Part D on Persons with Severe Mental Illness
neuroscienceCME Webcast
Premiere Date: Wednesday, February 6, 2008Additional Webcast Date:
Wednesday, February 27, 2008
12:00 PM - 1:00 PM ET
This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, February 27, 2009
Note: Credit Is No Longer Available
 | Daniel Carpenter, PhD Senior Vice President Chief Information Officer Comprehensive NeuroScience, Inc. White Plains, NY |
 | Carol L. Alter, MD Associate Professor of Psychiatry Director of Policy and Community Outreach Georgetown University Hospital Washington, DC |
 | Elizabeth V. Delesante, MD Psychiatrist Central Lakes Medical Clinic Crosby, MN |
Patients with severe mental illness (SMI) have a higher prevalence of medical conditions than the general
population, and generate more than twice the overall healthcare costs.(1) Contributing to this problem
are the general under-recognition of medical conditions in patients with SMI and their general lack of
access to quality care.(2) Thus, it is not surprising that patients with SMI are substantially impacted by policy
decisions that revise Medicaid eligibility standards, lower payments to providers, and complicate access
to new medications in an attempt to control rising healthcare costs. In particular, the implementation of
Medicare (MMA) Part D, which shifted pharmacy dollars to Medicare for dually eligible individuals, has had
a significant impact on this population. A recent survey of psychiatrists indicated that MMA Part D has
contributed to confusion and problems for physicians in maintaining continuity of care for SMI patients.(3)
This situation has created a strong impetus for expanding strategies for delivering highly cost-effective care
to SMI patients. In this interactive webcast, faculty will review key components of MMA Part D that impact
SMI patients and identify strategies to ensure continuous care and maximize the likelihood of a positive
outcome.
- Buck J, Teich J, Miller K. Use of mental health and substance abuse services among high-cost Medicaid enrollees. Adm Policy Ment Health 2003;31:3-14.
- Nasrallah H. An overview of common comorbidities in patients with schizophrenia. J Clin Psychiatry 2005;66:3-4.
- West JC, Wilk JE, Muszynski IL, et al. Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit. Am J Psychiatry 2007;164:700-701.
The goal of this activity is to educate practitioners about the impact of Medicare Part D on patients with severe mental illness and to provide guidance on strategies for delivering optimal care to these patients in light of policy restrictions.
At the end of this CE activity, participants should be able to:
- Identify the ways in which Medicare Part D impacts patients.
- Describe the clinical challenges posed by Medicare Part D.
- Delineate strategies for obtaining Medicare authorization for optimal pharmacotherapy.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals who treat patients with severe mental illness.
CME Credit (Physicians):
This activity has been planned and
implemented in accordance with the Essential
Areas and Policies of the Accreditation Council
for Continuing Medical Education through
the joint sponsorship of CME Outfitters, LLC, and Expert
Knowledge Systems, an educational division of Comprehensive
NeuroScience, Inc. CME Outfitters, LLC, is accredited by the
ACCME to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this educational activity for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
CME Outfitters, LLC, is an approved
provider of continuing nursing education by the New York State
Nurses Association, an accredited approver by the American
Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned code 6WASUP-PRV-0630. 1.0 contact hours will be awarded upon successful completion. This activity is co-provided with Expert Knowledge Systems, an educational
division of Comprehensive NeuroScience, Inc.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
CEP Credit (Psychologists):
CME Outfitters is approved by
the American Psychological Association to sponsor continuing
education for psychologists. CME Outfitters maintains
responsibility for this program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was approved
by the National Association of Social Workers (provider
#886407722) for 1 continuing education contact hour.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-999-08-006-L01-P (live presentation) 376-999-08-006-H01-P (recorded programs)
Post-tests, credit request forms, and activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required).
Joint Sponsorship
CME Outfitters gratefully acknowledges the contributions of Expert Knowledge Systems, an educational division of Comprehensive NeuroScience, Inc., as its joint sponsor for this continuing education activity.
Carol L. Alter, MD
Dr. Alter is the Director of Policy and Community Outreach and an Associate Professor in the Georgetown University Department
of Psychiatry. In addition she serves as the Executive Director of Treatment Effectiveness Now (“TEN Project”) a private, non-profit
policy action organization, dedicated to educating public officials, advocates and professionals about the clinical and policy
implications of evidence-based treatment for co-occurring medical and psychiatric disorders.
Dr. Alter is a psychiatrist with over 20 years experience in diverse settings in healthcare including clinical practice, research,
administration, healthcare delivery and the pharmaceutical industry. Her clinical and academic areas of interest focus on the
psychiatric care of AIDS and oncology patients. She is the author of numerous peer-reviewed manuscripts, monographs, and
book chapters related to psychosomatic medicine and access to psychiatric care.
Dr. Alter has been an active participant and leader in several professional organizations, including the American Psychiatric
Association where she participates in several committees related to Psychosomatic Medicine, Managed Care and
Reimbursement, the Academy of Psychosomatic Medicine, where she is currently the Vice President and the American
Psychosocial Oncology Society, where she sits on the Board of Directors.
Among numerous honors, she received a Special Recognition Award from the Academy of Psychosomatic Medicine in 1997 for
her advocacy work.
Dr. Alter received her medical degree from the George Washington University in 1985 and did her psychiatric training at the Mayo
Clinic, Cornell University Medical College and the Memorial Sloan Kettering Cancer Center.
Elizabeth V. Delesante, MD
Dr. Delesante is a psychiatrist in a multispecialty clinic in rural central Minnesota. She received the Paul Wellstone Patient
Advocacy Award in May 2007 for her work on Medicare Part D. Dr. Delesante received her bachelor’s degree in sociology at
Auburn University and her medical degree at the Medical College of Georgia in 1984. She completed her residency in psychiatry
at East Carolina University School of Medicine in 1992. Dr. Delesante is currently a member of the American Psychiatric
Association, the Minnesota Psychiatric Society, the National Alliance on Mental Illness, and the Minnesota Medical Association.
Daniel Carpenter, PhD, Moderator
Dr. Carpenter is a clinical psychologist with broad training and experience in clinical, technical, and research settings. He was
a co-author of the Expert Consensus Methodology for quantifying expert opinion and has taken the lead in putting together
the faculty teams for the Expert Consensus Guidelines Series. Dr. Carpenter trained at the Cornell University Medical College
Department of Psychiatry where he also served as a Research Fellow by handling the data management and analysis for studies
involving the delivery of psychiatric care. He then served as the Director of Clinical Data Systems for Merit Behavioral Care
Corporation where he reported to the Chief Medical Officer and implemented several data-driven research and development
and quality improvement initiatives. He left Merit in 1998 with John Docherty to help found Comprehensive NeuroScience, Inc.,
a private company dedicated to improving medical care by increasing the efficiency of clinical trials and educating clinicians
regarding best practices.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE
activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or
devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has
evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure,
use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant
information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Alter has no financial relationships to disclose in regard to the products and/or services discussed in this activity.
Dr. Delesante has disclosed that she is on the speakers bureaus of AstraZeneca, Bristol-Myers Squibb Company, Forest
Pharmaceuticals, Inc., and Janssen.
Dr. Carpenter has disclosed that he is employed by Comprehensive NeuroScience, Inc.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The
faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational
uses (any uses not approved by the FDA) of products or devices.
The joint sponsors, the faculty, and Eli Lilly and Company do not endorse the use of any product outside of the FDA labeled
indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this
activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WC-002-020608-11
